Degarelix

Drug Profile

Degarelix

Alternative Names: ASP-3550; Degarelix acetate; FE-200486; Firmagon; Gonax; Uglypeptide-1

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Astellas Pharma; Ferring Pharmaceuticals
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 01 May 2017 Ferring Pharmaceuticals completes a phase III extension trial for Prostate cancer in China (NCT02015871)
  • 07 Oct 2016 Efficacy data from the pooled analysis of phase III trials in Prostate cancer presented at the 41st European Society for Medical Oncology Congress
  • 01 Aug 2016 Astellas Pharma completes a phase III trial for Prostate cancer in Japan (NCT01964170)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top